Literature DB >> 17517834

Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.

Anne J Lenaerts1, Donald Hoff, Sahar Aly, Stefan Ehlers, Koen Andries, Luis Cantarero, Ian M Orme, Randall J Basaraba.   

Abstract

The lengthy chemotherapy of tuberculosis reflects the ability of a small subpopulation of Mycobacterium tuberculosis bacteria to persist in infected individuals. To date, the exact location of these persisting bacteria is not known. Lung lesions in guinea pigs infected with M. tuberculosis have striking similarities, such as necrosis, mineralization, and hypoxia, to natural infections in humans. Guinea pigs develop necrotic primary lesions after aerosol infection that differ in their morphology compared to secondary lesions resulting from hematogenous dissemination. In infected guinea pigs conventional therapy for tuberculosis during 6 weeks reduced the bacterial load by 1.7 logs in the lungs and, although this completely reversed lung inflammation associated with secondary lesions, the primary granulomas remained largely unaffected. Treatment of animals with the experimental drug R207910 (TMC207) for 6 weeks was highly effective with almost complete eradication of the bacteria throughout both the primary and the secondary lesions. Most importantly, the few remnants of acid-fast bacilli remaining after R207910 treatment were to be found extracellular, in a microenvironment of residual primary lesion necrosis with incomplete dystrophic calcification. This zone of the primary granuloma is hypoxic and is morphologically similar to what has been described for human lung lesions. These results show that this acellular rim may, therefore, be a primary location of persisting bacilli withstanding drug treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17517834      PMCID: PMC2043239          DOI: 10.1128/AAC.00276-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  44 in total

Review 1.  Current progress in tuberculosis vaccine development.

Authors:  Ian M Orme
Journal:  Vaccine       Date:  2005-03-18       Impact factor: 3.641

2.  Mycobacterial biofilms: a greasy way to hold it together.

Authors:  María Mercedes Zambrano; Roberto Kolter
Journal:  Cell       Date:  2005-12-02       Impact factor: 41.582

3.  Replication dynamics of Mycobacterium tuberculosis in chronically infected mice.

Authors:  Ernesto J Muñoz-Elías; Juliano Timm; Tania Botha; Wai-Tsing Chan; James E Gomez; John D McKinney
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.

Authors:  C K Stover; P Warrener; D R VanDevanter; D R Sherman; T M Arain; M H Langhorne; S W Anderson; J A Towell; Y Yuan; D N McMurray; B N Kreiswirth; C E Barry; W R Baker
Journal:  Nature       Date:  2000-06-22       Impact factor: 49.962

5.  Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.

Authors:  Sang Hyun Cho; Saradee Warit; Baojie Wan; Chang Hwa Hwang; Guido F Pauli; Scott G Franzblau
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

6.  Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis.

Authors:  Christine M Johnson; Rajesh Pandey; Sadhna Sharma; G K Khuller; Randall J Basaraba; Ian M Orme; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

7.  Modified immunohistological staining allows detection of Ziehl-Neelsen-negative Mycobacterium tuberculosis organisms and their precise localization in human tissue.

Authors:  Timo Ulrichs; Michael Lefmann; Maja Reich; Lars Morawietz; Andreas Roth; Volker Brinkmann; George A Kosmiadi; Peter Seiler; Peter Aichele; Helmut Hahn; Veit Krenn; Ulf B Göbel; Stefan H E Kaufmann
Journal:  J Pathol       Date:  2005-04       Impact factor: 7.996

8.  Designer arrays for defined mutant analysis to detect genes essential for survival of Mycobacterium tuberculosis in mouse lungs.

Authors:  Gyanu Lamichhane; Sandeep Tyagi; William R Bishai
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

9.  Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.

Authors:  Sandeep Tyagi; E Nuermberger; T Yoshimatsu; K Williams; I Rosenthal; N Lounis; W Bishai; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

10.  Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.

Authors:  Anne J Lenaerts; Veronica Gruppo; Karen S Marietta; Christine M Johnson; Diane K Driscoll; Nicholas M Tompkins; Jerry D Rose; Robert C Reynolds; Ian M Orme
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

View more
  114 in total

Review 1.  TMC207: the first compound of a new class of potent anti-tuberculosis drugs.

Authors:  Alberto Matteelli; Anna Cc Carvalho; Kelly E Dooley; Afranio Kritski
Journal:  Future Microbiol       Date:  2010-06       Impact factor: 3.165

2.  The stringent response is required for full virulence of Mycobacterium tuberculosis in guinea pigs.

Authors:  Lee G Klinkenberg; Jong-Hee Lee; William R Bishai; Petros C Karakousis
Journal:  J Infect Dis       Date:  2010-11-01       Impact factor: 5.226

3.  Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.

Authors:  Zahoor Ahmad; Mostafa M Fraig; Gregory P Bisson; Eric L Nuermberger; Jacques H Grosset; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

Review 4.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 5.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

6.  The 52nd Annual Wind River Conference On Prokaryotic Biology--2008.

Authors:  E Mann; M A Zaunbrecher; K Hitz; G Churchward
Journal:  J Bacteriol       Date:  2008-10-17       Impact factor: 3.490

7.  Essential engagement of Toll-like receptor 2 in initiation of early protective Th1 response against rough variants of Mycobacterium abscessus.

Authors:  Jong-Seok Kim; Min-Jung Kang; Woo Sik Kim; Seung Jung Han; Hong Min Kim; Ho Won Kim; Kee Woong Kwon; So Jeong Kim; Seung Bin Cha; Seok-Yong Eum; Won-Jung Koh; Sang-Nae Cho; Jong-Hwan Park; Sung Jae Shin
Journal:  Infect Immun       Date:  2015-02-02       Impact factor: 3.441

8.  An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions.

Authors:  Jansy P Sarathy; Hsin-Pin Ho Liang; Danielle Weiner; Jacqueline Gonzales; Laura E Via; Véronique Dartois
Journal:  J Vis Exp       Date:  2017-05-08       Impact factor: 1.355

9.  The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis.

Authors:  Bintou A Ahidjo; Mariama C Maiga; Elizabeth A Ihms; Mamoudou Maiga; Alvaro A Ordonez; Laurene S Cheung; Sarah Beck; Bruno B Andrade; Sanjay Jain; William R Bishai
Journal:  JCI Insight       Date:  2016-09-08

10.  Prediction of Drug Penetration in Tuberculosis Lesions.

Authors:  Jansy P Sarathy; Fabio Zuccotto; Ho Hsinpin; Lars Sandberg; Laura E Via; Gwendolyn A Marriner; Thierry Masquelin; Paul Wyatt; Peter Ray; Véronique Dartois
Journal:  ACS Infect Dis       Date:  2016-07-06       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.